Время до отказа от лечения признано валидным показателем эффективности в онкологических исследованиях

Time to treatment failure (TTF) is associated with progression-free survival (PFS) across tumor types and treatment modalities in advanced cancer, according to results published in JCO Precision Oncology. The findings suggest that TTF can serve as a valid and clinically meaningful endpoint for use in pragmatic oncology trials, the researchers wrote. “[TTF] correlates well with PFS and captures broader dimensions of treatment effectiveness, integrating efficacy, tolerability, and real-world sustainability,” the researchers wrote. “By reflecting both survival benefit and treatment-limiting toxicity, TTF offers valuable complementary insights for pragmatic oncology trials and [real-world data] analyses.” The researchers conducted a systematic search of the literature to identify randomized trials in advanced solid tumor malignancies evaluating the therapeutic benefit of systemic therapies. They included trials published from 2010 to 2023 that used a superiority design, and reported outcomes for PFS, TTF, and overall survival (OS). Researchers assessed correlations between hazard ratios for TTF and PFS using linear regression analysis, and stratified the results by prognosis. Data from 58 trials involving 19,099 patients across 13 tumor types were included. Six of the included trials had 2 investigational treatment arms, each examined against a common control group. These studies were treated as 2 distinct trial units for analysis purposes. The researchers found that TTF and PFS were strongly correlated in both poor prognosis (correlation coefficient [r], 0.81; 95% CI, 0.59-0.94) and good prognosis (r, 0.79; 95% CI, 0.60-0.91) groups. In the intervention arm, median TTF and PFS were comparable in poor prognosis trials (9.6 vs 11.0 months; P =.12). The correlation was not as robust in good prognosis settings (16.8 vs 23.0 months; P <.001). Overall, the correlation was strongest in chemotherapy-based (r, 0.93-0.96) and first-line (r, 0.88-0.90) trials, and weaker in targeted-therapy (r, 0.35-0.55) and later-line settings (r, 0.35-0.82). “Our work supports the use of TTF as a practical, patient-centered measure of net clinical benefit, and highlights its suitability as a fit-for-purpose endpoint in a contemporary pragmatic trial design,” the study authors wrote. Disclosures: There was no financial support listed for this study. Some authors disclosed conflicts of interest. Please see the original reference for complete disclosures. References: Dalrymple J, Symons R, Sjoquist KM, et al. Time to Treatment Failure as an End Point in Pragmatic Oncology Trials: Association With Progression-Free Survival Across Randomized Studies. JCO Precis Oncol. 2026;10(7):e2600011. doi:10.1200/PO-26-00011